HugginsC., HodgesC.: The effect of castration, of oestrogens and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res., 1; 293 (1941).
2.
The coronary drug project research group:Initial findings leading to modification of its research protocol. J.A.M.A., 214; 1303 (1970).
3.
Editoriale:Oestrogens and thromboembolism. Brit. med. J., 2; 189 (1970).
4.
GlashanR., RobinsonM.: Cardiovascular complication in the treatment of prostatic carcinoma. Brit. J. Urol., 53; 624 (1981).
5.
BlackardC.: Veterans Administration Co-operative Urological Research Groups studies of carcinoma of the prostate: a review. Cancer Chemoth., 59; 225 (1975).
6.
ByarsD.: Veterans Administration Co-operative Urological Research Groups studies of cancer of the prostate. Cancer, 32; 1126 (1973).
7.
AbbouC.: Treatment of prostatic cancer with diethylstilbestrol and detection of vascular risks. Presse méd., 9; 1067 (1975).
8.
BullerH.: Estrogen-induced deficiency and decrease in antithrombin III activity in patiens with prostatic cancer. J. Urol., 128; 72 (1982).
9.
DobbsM.: Clotting predisposition in carcinoma of the prostate. J. Urol., 123; 706 (1982).
10.
BlackardC., MellingerG., GleasonD.: Treatment of stage I carcinoma of the prostate: a preliminary report. J. Urol., 106; 729 (1971).
11.
BailarJ., ByarD.: Estrogen treatment for cancer of the prostate. Early risults with 3 doses of diethylstilbestrol and placebo. Cancer, 26; 257 (1970).
12.
SegalS., MarbergerH., FlocksR.: Tissue distribution of stilbestrol diphosphate: concentration in prostatic tissue. J. Urol., 81; 474 (1959).
13.
BezziE.: Associazioni terapeutiche nel carcinoma della prostata. Urologia, 47; 106 (1980).
14.
BlackardC.: Incidence of cardiovascular disease and death in patiens receiving diethylstilbestrol for carcinoma of the prostate. Cancer, 26; 249 (1970).
15.
BracciU.: Antiandrogens in the treatment of prostatic cancer. Eur. Urol., 5; 303 (1979).
